Home > Traitements Recherche > Hepatitis C: Shame on Gilead!

Hepatitis C: Shame on Gilead!

Thursday 25 July 2013

All the versions of this article: [English] [français]

Hepatitis C: Shame on Gilead!

Version Française ici

People living with HCV who are in an urgent need of new treatments should get an early access to compounds that are in their latest stage of development, and therefore not yet on the market. The French early access system called ATU (Temporary Authorization of Use) allows this early access.

This morning activists from Act Up-Paris went to Boulogne-Billancourt to the Gilead Sciences Inc. French headquarters, to remind the company that it must follow the advice of the National Security Agency of Drugs (ANSM). Gilead refuses to give early access to sofosbuvir to patients who received a nominative ATU from ANSM, because they were in a therapeutic impasse with the molecules currently available on the market. The activists put up posters on the facade and around the headquarters of the firm. The attitude of Gilead has been denounced by the coalition TRT-5.

Laure Pora, president of Act Up-Paris, said: "For Gilead, monopolistic logic primes on therapeutic requirements; compassionate access sofosbuvir is not the only example. If Gilead continues in this outrageous attitude, we will ask the members of the Economic Committee of Health Products, which sets the price of drugs, to punish them financially."

Pour recueillir des informations sur les ATU des molécules anti-hépatite C en cours de développement, le groupe a mis en place un observatoire qui peut-être alimenté par les malades, leurs proches, les médecins et les associations : http://www.actupparis.org/spip.php?article5207

Full disclosure : in 2013, Act Up-Paris received a €40,000 grant from Gilead.